{"disease":{"id":"nonalcoholic-steatohepatitis-nash","name":"nonalcoholic steatohepatitis nash"},"drugs":{"marketed":[{"drug_id":"resmetirom","indication_name":"Noncirrhotic Nonalcoholic Steatohepatitis (NASH)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"RESMETIROM","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"Thyroid Hormone Receptor beta Agonist [EPC]","quality_score":30,"revenue":null,"mechanism":null}],"pipeline":[{"drug_id":"pf-05221304","indication_name":"Nonalcoholic steatohepatitis (NASH)","indication_type":"pipeline","phase":"Phase 2","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-05221304","generic_name":"pf-05221304","company_name":"Pfizer Inc.","drug_phase":"discontinued","molecular_target":"Acetyl-CoA carboxylase (ACC1 and ACC2)","drug_class":"Acetyl-CoA carboxylase inhibitor","quality_score":27,"revenue":null,"mechanism":"Selective inhibitor of acetyl-CoA carboxylase (ACC1/ACC2) that reduces hepatic lipogenesis and promotes fatty acid oxidation."}],"offLabel":[],"totalMarketed":1,"totalPipeline":1},"trials":{"data":[{"nct_id":"NCT07336563","title":"ENDOCARE-SCREEN: Metabolic Liver Dysfunction Screening Study","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":10000,"lead_sponsor_name":"Jarosław Drobnik","has_results":false},{"nct_id":"NCT04255069","title":"A Study to Evaluate the Efficacy and Safety of JKB-122 in Patients With NASH and Fibrosis","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":300,"lead_sponsor_name":"TaiwanJ Pharmaceuticals Co., Ltd","has_results":false},{"nct_id":"NCT02443116","title":"Study of NGM282 in Patients With Nonalcoholic Steatohepatitis (NASH)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":254,"lead_sponsor_name":"NGM Biopharmaceuticals, Inc","has_results":true},{"nct_id":"NCT04880031","title":"A Study of BOS-580 in Obese Subjects at Risk for, or With Biopsy-confirmed, Nonalcoholic Steatohepatitis (NASH) With an Extension","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":231,"lead_sponsor_name":"Boston Pharmaceuticals","has_results":false},{"nct_id":"NCT02781584","title":"Safety, Tolerability, and Efficacy of Selonsertib, Firsocostat, and Cilofexor in Adults With Nonalcoholic Steatohepatitis (NASH)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":220,"lead_sponsor_name":"Gilead Sciences","has_results":true},{"nct_id":"NCT05623189","title":"HTD1801 in Adults With Nonalcoholic Steatohepatitis and Liver Fibrosis Who Have Type 2 Diabetes or Pre-Diabetes","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":218,"lead_sponsor_name":"HighTide Biopharma Pty Ltd","has_results":false},{"nct_id":"NCT05692492","title":"A Randomized, Double-blind, Placebo-controlled Study of ZSP1601 in Adult Subjects With Nonalcoholic Steatohepatitis (NASH)","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":180,"lead_sponsor_name":"Guangdong Raynovent Biotech Co., Ltd","has_results":false},{"nct_id":"NCT04104321","title":"A Clinical Study to Evaluate the Efficacy and Safety of Aramchol in Subjects With NASH (ARMOR)","phase":"PHASE3","overall_status":"SUSPENDED","enrollment_count":157,"lead_sponsor_name":"Galmed Research and Development, Ltd.","has_results":true},{"nct_id":"NCT02854605","title":"Evaluating the Safety, Tolerability, and Efficacy of GS-9674 in Participants With Nonalcoholic Steatohepatitis (NASH)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":140,"lead_sponsor_name":"Gilead Sciences","has_results":true},{"nct_id":"NCT06216041","title":"To Evaluate the Safety, Tolerability, Pharmacokinetics and Food Effects of IMM-H014 in Healthy Subjects","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":138,"lead_sponsor_name":"Changchun Intellicrown Pharmaceutical Co. LTD","has_results":false},{"nct_id":"NCT02856555","title":"Study to Evaluate Safety, Tolerability, and Efficacy of GS-0976 in Adults With Nonalcoholic Steatohepatitis","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":127,"lead_sponsor_name":"Gilead Sciences","has_results":true},{"nct_id":"NCT04267393","title":"Safety and Effectiveness of BMS-986263 in Adults With Compensated Cirrhosis (Liver Disease) From Nonalcoholic Steatohepatitis (NASH)","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":124,"lead_sponsor_name":"Bristol-Myers Squibb","has_results":true},{"nct_id":"NCT02654002","title":"Study in Healthy Volunteers to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GS-9674 (Cilofexor), and the Effect of Food on GS-9674 Pharmacokinetics and Pharmacodynamics","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":120,"lead_sponsor_name":"Gilead Sciences","has_results":true},{"nct_id":"NCT04913090","title":"A Phase I Clinical Trial of XZP-5610 Tablets in Healthy Subjects","phase":"PHASE1","overall_status":"UNKNOWN","enrollment_count":112,"lead_sponsor_name":"Xuanzhu Biopharmaceutical Co., Ltd.","has_results":false},{"nct_id":"NCT03572465","title":"Quantitative Ultrasound Techniques for Diagnosis of Nonalcoholic Steatohepatitis","phase":"","overall_status":"RECRUITING","enrollment_count":102,"lead_sponsor_name":"Centre hospitalier de l'Université de Montréal (CHUM)","has_results":false},{"nct_id":"NCT04977661","title":"Comparing the Effects of Vitamin E, Ursodeoxycholic Acid and Pentoxyfylline on Egyptian Non-alcoholic Steatohepatitis (NASH) Patients","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":102,"lead_sponsor_name":"Kafrelsheikh University","has_results":false},{"nct_id":"NCT05591079","title":"A Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of CS0159 in Subjects With NASH","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":99,"lead_sponsor_name":"Cascade Pharmaceuticals, Inc","has_results":false},{"nct_id":"NCT03392779","title":"Study in Chinese Healthy Adults to Evaluate the Safety, Tolerability and Pharmacokinetics on ZSP1601, and the Effect of Food on ZSP1601 Pharmacokinetics","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":94,"lead_sponsor_name":"Guangdong Zhongsheng Pharmaceutical Co., Ltd.","has_results":false},{"nct_id":"NCT04521114","title":"Leronlimab (PRO 140) in Patients With Nonalcoholic Steatohepatitis","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":87,"lead_sponsor_name":"CytoDyn, Inc.","has_results":true},{"nct_id":"NCT04165343","title":"Evaluation of Multi-Organ Metabolism and Perfusion in NAFLD by Total Body Dynamic PET Scan on EXPLORER","phase":"","overall_status":"COMPLETED","enrollment_count":81,"lead_sponsor_name":"University of California, Davis","has_results":false},{"nct_id":"NCT02891408","title":"Study to Evaluate the Pharmacokinetics of Firsocostat or Fenofibrate in Adults With Normal and Impaired Hepatic Function","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":74,"lead_sponsor_name":"Gilead Sciences","has_results":true},{"nct_id":"NCT05117489","title":"A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Patients With Presumed Nonalcoholic Steatohepatitis (NASH)","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":70,"lead_sponsor_name":"Corcept Therapeutics","has_results":false},{"nct_id":"NCT04546984","title":"Multiple Dose Safety, Tolerability, PK，PD and Food Effect Study of HEC96719 in Healthy Adult Subjects","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":66,"lead_sponsor_name":"Sunshine Lake Pharma Co., Ltd.","has_results":false},{"nct_id":"NCT04194242","title":"The Tolerability , Pharmacokinetics and Pharmacodynamics Study of HEC96719 Tablets in Healthy Adult Subjects","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":64,"lead_sponsor_name":"Sunshine Lake Pharma Co., Ltd.","has_results":false},{"nct_id":"NCT02196831","title":"Tesamorelin Effects on Liver Fat and Histology in HIV","phase":"NA","overall_status":"COMPLETED","enrollment_count":61,"lead_sponsor_name":"Massachusetts General Hospital","has_results":true},{"nct_id":"NCT05842512","title":"Study of ADI-PEG 20 Versus Placebo in Subjects With NASH","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":60,"lead_sponsor_name":"Polaris Group","has_results":false},{"nct_id":"NCT02808312","title":"Pharmacokinetics and Pharmacodynamics of Cilofexor in Adults With Normal and Impaired Hepatic Function","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":57,"lead_sponsor_name":"Gilead Sciences","has_results":true},{"nct_id":"NCT04134091","title":"The Efficacy, Safety and Tolerability of Oral LPCN 1144 in Subjects With Nonalcoholic Steatohepatitis","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":56,"lead_sponsor_name":"Lipocine Inc.","has_results":true},{"nct_id":"NCT03861819","title":"Feasibility of VIIT in Adults With NASH","phase":"NA","overall_status":"COMPLETED","enrollment_count":24,"lead_sponsor_name":"Duke University","has_results":false},{"nct_id":"NCT05320146","title":"A Sub Study of the Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Patients With Presumed Nonalcoholic Steatohepatitis (NASH)","phase":"","overall_status":"COMPLETED","enrollment_count":22,"lead_sponsor_name":"Corcept Therapeutics","has_results":false},{"nct_id":"NCT05560607","title":"Knockdown of HSD17B13 mRNA, Pharmacokinetics, Safety, and Tolerability, of AZD7503 in Non-Alcoholic Fatty Liver Disease","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":19,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT06195943","title":"Feasibility, Safety and Acceptability of a Mobile Health Delivered Exercise Training Program in Patients With Nonalcoholic Steatohepatitis","phase":"NA","overall_status":"COMPLETED","enrollment_count":17,"lead_sponsor_name":"Milton S. Hershey Medical Center","has_results":false},{"nct_id":"NCT04004325","title":"A Study of FT 4101 in Overweight/Obese Participants With Non-alcoholic Steatohepatitis","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":14,"lead_sponsor_name":"Forma Therapeutics, Inc.","has_results":true},{"nct_id":"NCT03823703","title":"Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Participants With Presumed Nonalcoholic Steatohepatitis (NASH)","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":12,"lead_sponsor_name":"Corcept Therapeutics","has_results":true},{"nct_id":"NCT06024408","title":"A Trial to Learn if Receiving ALN-PNP siRNA is Safe and Well Tolerated, and How it Works in Adult Participants With Nonalcoholic Fatty Liver Disease (NAFLD) and a Genetic Risk Factor","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":9,"lead_sponsor_name":"Regeneron Pharmaceuticals","has_results":false},{"nct_id":"NCT06037577","title":"Subcutaneous Doses of CM-101 as a Treatment for Medical Conditions Involving Inflammatory and Fibrotic Mechanisms in Healthy Male Subjects","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":8,"lead_sponsor_name":"ChemomAb Ltd.","has_results":false},{"nct_id":"NCT04616014","title":"A Study of Oral Insulin to Reduce Liver Fat Content in Type 2 Diabetes Patients With Nonalcoholic Steatohepatitis (NASH)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":7,"lead_sponsor_name":"Oramed, Ltd.","has_results":true},{"nct_id":"NCT03332940","title":"Safety Evaluation of IV Tc 99m Tilmanocept and Comparison of Imaging With Sulfur Colloid in Subjects With and Without NASH","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":6,"lead_sponsor_name":"Navidea Biopharmaceuticals","has_results":false},{"nct_id":"NCT04565717","title":"A Study of ALN-HSD in Healthy Adult Subjects and Adult Patients With Nonalcoholic Steatohepatitis (NASH)","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":6,"lead_sponsor_name":"Alnylam Pharmaceuticals","has_results":false},{"nct_id":"NCT05118360","title":"Study to Evaluate the Safety, Tolerability, and Efficacy of ASC41 in Adults With NASH","phase":"PHASE2","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"Gannex Pharma Co., Ltd.","has_results":false}],"total":40},"guidelines":[],"source":"Drug Landscape verified database"}